Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020
Kelly Valla, PharmD, BCOP
J Adv Pract Oncol 2021;12(suppl 1):23-26 |
© 2021 Harborside™
At the 2020 SOHO Annual Meeting, Alex F. Herrera, MD, of City of Hope, discussed the integration of novel agents into the management of patients with relapsed or refractory Hodgkin lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses insights from this session for advanced practitioners.
For access to the full length article, please sign in